Dear Doctor Letter (Rote-Hand-Brief) on Angiox® (bivalirudin): Inappropriate "bolus-only" dosing for PCI
2013.01.08
Active substance: bivalirudin
Communication for healthcare professionals based on reports of IV bolus injections of Angiox® (bivalirudin) alone without immediately following IV infusions. The resulting sub-therapeutic plasma concentrations bear the risk of ineffective ischaemic protection during percutaneous coronary intervention (PCI).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN